Product profile · United States
FARXIGA
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| 6515117 | 2025-10-04 | DS/DP/U U-2139 | — | — | — | — | — | — |
| 6515117 | 2025-10-04 | DS/DP/U U-493 | — | — | — | — | — | — |
| 6515117 | 2026-04-04 | — — | — | — | — | — | 2026-04-04 | — |
| 8329648 | 2026-08-18 | U U-2213 | — | — | — | — | — | — |
| 8329648 | 2026-08-18 | U U-2139 | — | — | — | — | — | — |
| 8329648 | 2026-08-18 | U U-2212 | — | — | — | — | — | — |
| 8906851 | 2026-08-18 | U U-2139 | — | — | — | — | — | — |
| 8329648 | 2027-02-18 | — — | — | — | — | — | 2027-02-18 | — |
| 8906851 | 2027-02-18 | — — | — | — | — | — | 2027-02-18 | — |
| 8501698 | 2027-06-20 | DP/U U-493 | — | — | — | — | — | — |
| 8501698 | 2027-12-20 | — — | — | — | — | — | 2027-12-20 | — |
| 8221786 | 2028-03-21 | DP — | — | — | — | — | — | — |
| 8361972 | 2028-03-21 | U U-493 | — | — | — | — | — | — |
| 8361972 | 2028-03-21 | U U-2139 | — | — | — | — | — | — |
| 8716251 | 2028-03-21 | DP — | — | — | — | — | — | — |
| 7851502 | 2028-08-19 | DP — | — | — | — | — | — | — |
| 8221786 | 2028-09-21 | — — | — | — | — | — | 2028-09-21 | — |
| 8361972 | 2028-09-21 | — — | — | — | — | — | 2028-09-21 | — |
| 8716251 | 2028-09-21 | — — | — | — | — | — | 2028-09-21 | — |
| 7851502 | 2029-02-19 | — — | — | — | — | — | 2029-02-19 | — |
| 7919598 | 2029-12-16 | DS — | — | — | — | — | — | — |
| 8721615 | 2030-01-18 | DP — | — | — | — | — | — | — |
| 8685934 | 2030-05-26 | U U-1522 | — | — | — | — | — | — |
| 7919598 | 2030-06-16 | — — | — | — | — | — | 2030-06-16 | — |
| 8721615 | 2030-07-18 | — — | — | — | — | — | 2030-07-18 | — |
| 8685934 | 2030-11-26 | — — | — | — | — | — | 2030-11-26 | — |
| 11826376 | 2039-07-18 | U U-3766 | — | — | — | — | — | — |
| 12472194 | 2039-07-18 | U U-4346 | — | — | — | — | — | — |
| 11826376 | 2040-01-18 | — — | — | — | — | — | 2040-01-18 | — |
| 12472194 | 2040-01-18 | — — | — | — | — | — | 2040-01-18 | — |
| 10973836 | 2040-03-09 | U U-3127 | — | — | — | — | — | — |
| 11903955 | 2040-03-09 | U U-3825 | — | — | — | — | — | — |
| 10973836 | 2040-09-09 | — — | — | — | — | — | 2040-09-09 | — |
| 11903955 | 2040-09-09 | — — | — | — | — | — | 2040-09-09 | — |
| 12213988 | 2041-04-01 | U U-4140 | — | — | — | — | — | — |
| 12409186 | 2041-04-01 | U U-4140 | — | — | — | — | — | — |
| 12213988 | 2041-10-01 | — — | — | — | — | — | 2041-10-01 | — |
| 12409186 | 2041-10-01 | — — | — | — | — | — | 2041-10-01 | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| M-298 | — | 2026-05-08 | — | — | — | — | Source | |
| PED | — | 2026-11-08 | — | — | — | — | Source | |
| NPP | — | 2027-06-12 | — | — | — | — | Source | |
| PED | — | 2027-12-12 | — | — | — | — | Source |
2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| 202293 / 002 | AUTHORIZED_GENERIC_REPORTED · AUTHORIZED_GENERIC_REPORTED | — | — | AstraZeneca AB | Y | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211439 / 002 | APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED | — | — | HETERO LABS UNIT III | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211442 / 002 | APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED | — | — | APOTEX INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211564 / 002 | APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED | — | — | GLENMARK GENERICS | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 216119 / 002 | APPLICATION_TENTATIVE_OBSERVATION · TENTATIVE_PRODUCT_SCOPE_UNVERIFIED | — | — | JIANGSU HANSOH PHARM | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211156 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | INVENTIA HEALTHCARE LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211312 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | SANDOZ INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211467 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | MICRO LABS LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211468 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | AUROBINDO PHARMA LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211470 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | BIOCON PHARMA LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211478 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | MSN LABORATORIES PRIVATE LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211482 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | AJANTA PHARMA LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211506 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | MACLEODS PHARMACEUTICALS LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211523 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211531 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | LUPIN LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211535 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | CIPLA LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211541 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | TEVA PHARMACEUTICALS USA INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211545 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | ALKEM LABORATORIES LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211560 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | ALEMBIC PHARMACEUTICALS LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 211582 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | — | ZYDUS PHARMACEUTICALS USA INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 1 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| 202293 / 002 | AstraZeneca AB | AUTHORIZED_GENERIC_REPORTED · AUTHORIZED_GENERIC_REPORTED | — | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 15 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| 211156 / 002 | INVENTIA HEALTHCARE LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211312 / 002 | SANDOZ INC | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211467 / 002 | MICRO LABS LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211468 / 002 | AUROBINDO PHARMA LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211470 / 002 | BIOCON PHARMA LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211478 / 002 | MSN LABORATORIES PRIVATE LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211482 / 002 | AJANTA PHARMA LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211506 / 002 | MACLEODS PHARMACEUTICALS LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211523 / 002 | AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211531 / 002 | LUPIN LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211535 / 002 | CIPLA LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211541 / 002 | TEVA PHARMACEUTICALS USA INC | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211545 / 002 | ALKEM LABORATORIES LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211560 / 002 | ALEMBIC PHARMACEUTICALS LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 211582 / 002 | ZYDUS PHARMACEUTICALS USA INC | FINAL_APPROVAL · FINAL_APPROVED | 2026-04-06 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
Decision evidence (1)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| GENERIC | 2026-04-06 | TERMINAL_GENERIC_BASIS | Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted. | Source |
Independent legal-event information
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.